Research Papers:

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination

Erika Nakatsuka, Kenjiro Sawada _, Koji Nakamura, Akihito Yoshimura, Yasuto Kinose, Michiko Kodama, Kae Hashimoto, Seiji Mabuchi, Hiroshi Makino, Eiichi Morii, Yoichi Yamaguchi, Takeshi Yanase, Akiko Itai, Ken-ichirou Morishige and Tadashi Kimura

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:89887-89902. https://doi.org/10.18632/oncotarget.20834

Metrics: PDF 1499 views  |   HTML 3135 views  |   ?  


Erika Nakatsuka1, Kenjiro Sawada1, Koji Nakamura1, Akihito Yoshimura1, Yasuto Kinose1, Michiko Kodama1, Kae Hashimoto1, Seiji Mabuchi1, Hiroshi Makino2, Eiichi Morii3, Yoichi Yamaguchi4, Takeshi Yanase4, Akiko Itai4, Ken-ichirou Morishige2 and Tadashi Kimura1

1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

2Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan

3Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

4IMMD Inc., Tokyo, Japan

Correspondence to:

Kenjiro Sawada, email: [email protected]

Keywords: ovarian cancer, PAI-1, IMD-4482, peritoneal dissemination, angiogenesis

Received: November 23, 2016    Accepted: August 06, 2017    Published: September 12, 2017


In the present study, the therapeutic potential of targeting plasminogen activator inhibitor-1 (PAI-1) in ovarian cancer was tested. Tissues samples from 154 cases of ovarian carcinoma were immunostained with anti-PAI-1 antibody, and the prognostic value was analyzed. Among the samples, 67% (104/154) showed strong PAI-1 expression; this was significantly associated with poor prognosis (progression-free survival: 20 vs. 31 months, P = 0.0033). In particular, among patients with stage II-IV serous adenocarcinoma, PAI-1 expression was an independent prognostic factor. The effect of a novel PAI-1 inhibitor, IMD-4482, on ovarian cancer cell lines was assessed and its therapeutic potential was examined using a xenograft mouse model of ovarian cancer. IMD-4482 inhibited in vitro cell adhesion to vitronectin in PAI-1-positive ovarian cancer cells, followed by the inhibition of extracellular signal-regulated kinase and focal adhesion kinase phosphorylation through dissociation of the PAI-urokinase receptor complex from integrin αVβ3. IMD-4482 caused G0/G1 cell arrest and inhibited the proliferation of PAI-1-positive ovarian cancer cells. In the xenograft model, IMD-4482 significantly inhibited peritoneal dissemination with the reduction of PAI-1 expression and the inhibition of focal adhesion kinase phosphorylation. Collectively, the functional inhibition of PAI-1 significantly inhibited ovarian cancer progression, and targeting PAI-1 may be a potential therapeutic strategy in ovarian cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20834